K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate
BD Smith, YL Kasamon, J Kowalski, C Gocke… - Clinical Cancer …, 2010 - AACR
… Targeting such minimal residual disease may lead to improved … Our manuscript describes
the clinical impact of a K562/GM-CSF … -colony stimulating factor (GM-CSF) is a vaccine derived …
the clinical impact of a K562/GM-CSF … -colony stimulating factor (GM-CSF) is a vaccine derived …
Gene transfer of GM-CSF, CD80 and CD154 cDNA enhances survival in a murine model of acute leukemia with persistence of a minimal residual disease
R Vereecque, G Buffenoir, C Preudhomme, D Hetuin… - Gene Therapy, 2000 - nature.com
… We analyzed the minimal residual disease by RT-PCR BCR/ABL in some surviving mice (…
-transduced cells and one mice from the GM-CSF vaccine group were positive by BCR/ABL RT-…
-transduced cells and one mice from the GM-CSF vaccine group were positive by BCR/ABL RT-…
Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF
R Mikysková, M Indrová, J Símová… - International …, 2004 - spandidos-publications.com
… dose of GMCSF-producing B9 cells. Local treatment of TC-1 SMRTD with rGM-CSF resulted
in a significant inhibition of tumour growth (P<0.05) and significant reduction of the tumour …
in a significant inhibition of tumour growth (P<0.05) and significant reduction of the tumour …
K562/GM-CSF vaccination reduces tumor burden, including achieving molecular remissions, in chronic myeloid leukemia (CML) patients (PTS) with residual disease …
B Smith, YL Kasamon, CB Miller, C Chia… - Journal of Clinical …, 2006 - ascopubs.org
… to produce GM-CSF. A pilot vaccination strategy was developed to determine if K562/GM-CSF …
responses in pts having persistent, measurable disease despite 1 or more years on IM. …
responses in pts having persistent, measurable disease despite 1 or more years on IM. …
[HTML][HTML] GM-CSF as therapy
JP Fruehauf, KM Kong, JG Jakowatz - Oncology (Williston Park), 2005 - her2support.org
… Notably, 6 of 7 responders but only 1 of 8 patients with disease progression developed
leukocytosis during therapy. Therefore, we conclude that continuous low-dose GM-CSF has …
leukocytosis during therapy. Therefore, we conclude that continuous low-dose GM-CSF has …
GM-CSF stimulation of immune response in minimal residual cancer
M Schulze, I Fackler-Schwalbe, F Lindemann… - Acute Leukemias VII …, 1998 - Springer
… Minimal residual disease in cancer can be detected by identification of epithelial tumor cells
in bone marrow using monoclonal antibodies directed against cytokeratin. The presence of …
in bone marrow using monoclonal antibodies directed against cytokeratin. The presence of …
Clinical uses of GM-CSF, a critical appraisal and update
M Arellano, S Lonial - Biologics: Targets and Therapy, 2008 - Taylor & Francis
… However, its benefit has been limited to patients with minimal residual disease, and dose-escalation
has been limited by significant systemic toxicities. The optimal use of cytokines may …
has been limited by significant systemic toxicities. The optimal use of cytokines may …
Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II (T4), III, and …
LE Spitler, RW Weber, RE Allen, J Meyer… - Journal of …, 2009 - journals.lww.com
… Adjuvant radiotherapy was allowed in patients in whom residual disease was suspected
postoperatively. Patients were not excluded if they had received prior chemotherapy, radiation …
postoperatively. Patients were not excluded if they had received prior chemotherapy, radiation …
The use of GM-CSF and G-CSF in the treatment of acute leukemias
JL Harousseau, D Wu - Leukemia & Lymphoma, 1995 - Taylor & Francis
… Indeed, as soon as recombinant GMCSF or G-CSF were available for medical practice, …
index'2-39 and the binding of GM-CSF or G-CSF to AML cells was studied and the receptors of …
index'2-39 and the binding of GM-CSF or G-CSF to AML cells was studied and the receptors of …
CD116 (GM-CSF-R)
M Dabusti, B Castagnari, S Moretti, L Ferrari… - JOURNAL OF …, 2001 - cris.unibo.it
… residual disease. Cellular CD116 expression was documented in > 50% M0 AML. Since
the activity of GM-CSF … hypothesised that the clinical use of GM-CSF in AML patients could be …
the activity of GM-CSF … hypothesised that the clinical use of GM-CSF in AML patients could be …
相关搜索
- minimal residual disease
- gm csf adjuvant therapy
- gm csf prostate cancer
- gm csf granulocyte macrophage
- gm csf cancer immunotherapy
- gm csf acute leukemias
- gm csf leukemia cells
- gm csf tumor cells
- residual disease on imatinib mesylate
- gm csf stimulation minimal residual cancer
- persistent residual disease
- molecular minimal residual disease party trial
- gm csf in malignant melanoma
- gm csf concentrations
- gm csf receptors
- recombinant gm csf